|
1
|
Ma X, Lin C and Zhen W: Cancer care in
China: a general review. Biomed Imaging Interv J.
4:e392008.PubMed/NCBI
|
|
2
|
Vigano M and Lampertico P: Antiviral drugs
for HBV liver disease. Expert Opin Biol Ther. 11:285–300. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yan H, Zhong G, Xu G, et al: Sodium
taurocholate cotransporting polypeptide is a functional receptor
for human hepatitis B and D virus. Elife. 1:e000492012.PubMed/NCBI
|
|
4
|
Roseman AM, Berriman JA, Wynne SA, Butler
PJ and Crowther RA: A structural model for maturation of the
hepatitis B virus core. Proc Natl Acad Sci USA. 102:15821–15826.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Deres K, Schroder CH, Paessens A, et al:
Inhibition of hepatitis B virus replication by drug-induced
depletion of nucleocapsids. Science. 299:893–896. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kulbachinskiy AV: Methods for selection of
aptamers to protein targets. Biochemistry (Moscow). 72:1505–1518.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sefah K, Shangguan D, Xiong X, O’Donoghue
MB and Tan W: Development of DNA aptamers using Cell-SELEX. Nat
Protoc. 5:1169–1185. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chakravarthy U, Adamis AP, Cunningham ETJ,
et al: Year 2 efficacy results of 2 randomized controlled clinical
trials of pegaptanib for neovascular age-related macular
degeneration. Ophthalmology. 113:1508.e1501–1508.e1525.
2006.PubMed/NCBI
|
|
9
|
Ng EW, Shima DT, Calias P, Cunningham ET
Jr, Guyer DR and Adamis AP: Pegaptanib, a targeted anti-VEGF
aptamer for ocular vascular disease. Nat Rev Drug Discov.
5:123–132. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ramalingam D, Duclair S, Datta SA,
Ellington A, Rein A and Prasad VR: RNA aptamers directed to human
immunodeficiency virus type 1 Gag polyprotein bind to the matrix
and nucleocapsid domains and inhibit virus production. J Virol.
85:305–314. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kikuchi K, Umehara T, Fukuda K, Kuno A,
Hasegawa T and Nishikawa S: A hepatitis C virus (HCV) internal
ribosome entry site (IRES) domain III-IV-targeted aptamer inhibits
translation by binding to an apical loop of domain IIId. Nucleic
Acids Res. 33:683–692. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kikuchi K, Umehara T, Nishikawa F, Fukuda
K, Hasegawa T and Nishikawa S: Increased inhibitory ability of
conjugated RNA aptamers against the HCV IRES. Biochem Biophys Res
Commun. 386:118–123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen F, Hu Y, Li D, Chen H and Zhang XL:
CS-SELEX generates high-affinity ssDNA aptamers as molecular probes
for hepatitis C virus envelope glycoprotein E2. PLoS One.
4:e81422009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Neff CP, Zhou J, Remling L, et al: An
aptamer-siRNA chimera suppresses HIV-1 viral loads and protects
from helper CD4+ T cell decline in humanized mice. Sci
Transl Med. 3:66ra662011.PubMed/NCBI
|
|
15
|
Zhou J, Li H, Li S, Zaia J and Rossi JJ:
Novel dual inhibitory function aptamer-siRNA delivery system for
HIV-1 therapy. Mol Ther. 16:1481–1489. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu J, Yang Y, Hu B, et al: Development of
HBsAg-binding aptamers that bind HepG2.2.15 cells via HBV surface
antigen. Virol Sin. 25:27–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Feng H, Beck J, Nassal M and Hu KH: A
SELEX-screened aptamer of human hepatitis B virus RNA encapsidation
signal suppresses viral replication. PLoS One. 6:e278622011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ray P and White RR: Aptamers for targeted
drug delivery. Pharmaceuticals. 3:1761–1778. 2010. View Article : Google Scholar
|
|
19
|
Jun-Bin S, Zhi C, Wei-Qin N and Jun F: A
quantitative method to detect HBV cccDNA by chimeric primer and
real-time polymerase chain reaction. J Virol Methods. 112:45–52.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang W, Ke W, Wu SS, et al: An
adenovirus-delivered peptide aptamer C1-1 targeting the core
protein of hepatitis B virus inhibits viral DNA replication and
production in vitro and in vivo. Peptides. 30:1816–1821. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Calvert J and Summers J: Two regions of an
avian hepadnavirus RNA pregenome are required in cis for
encapsidation. J Virol. 68:2084–2090. 1994.PubMed/NCBI
|
|
22
|
Lu B, Wang J, Zhang J, et al: Screening
and verification of ssDNA aptamers targeting human hepatocellular
carcinoma. Acta Biochim Biophys Sin (Shanghai). 46:128–135. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Devi U and Locarnini S: Hepatitis B
antivirals and resistance. Curr Opin Virol. 3:495–500. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ferapontova EE and Gothelf KV: Recent
advances in electrochemical aptamer-based sensors. Curr Org Chem.
15:498–505. 2011. View Article : Google Scholar
|
|
25
|
Chu TC, Marks JW III, Lavery LA, et al:
Aptamer: toxin conjugates that specifically target prostate tumor
cells. Cancer Res. 66:5989–5992. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang JC, Dhason MS and Zlotnick A:
Structural organization of pregenomic RNA and the carboxy-terminal
domain of the capsid protein of hepatitis B virus. PLoS Pathog.
8:e10029192012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vanlandschoot P, Van Houtte F, Serruys B
and Leroux-Roels G: The arginine-rich carboxy-terminal domain of
the hepatitis B virus core protein mediates attachment of
nucleocapsids to cell-surface-expressed heparan sulfate. J Gen
Virol. 86:75–84. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jammeh S, Tavner F, Watson R, Thomas HC
and Karayiannis P: Effect of basal core promoter and pre-core
mutations on hepatitis B virus replication. J Gen Virol.
89:901–909. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo H, Jiang D, Zhou T, Cuconati A, Block
TM and Guo JT: Characterization of the intracellular deproteinized
relaxed circular DNA of hepatitis B virus: an intermediate of
covalently closed circular DNA formation. J Virol. 81:12472–12484.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schmitz A, Schwarz A, Foss M, et al:
Nucleoporin 153 arrests the nuclear import of hepatitis B virus
capsids in the nuclear basket. PLoS Pathog. 6:e10007412010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Masri HP and Cornelissen CN: Specific
ligand binding attributable to individual epitopes of gonococcal
transferrin binding protein A. Infect Immun. 70:732–740. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamada N and Tanoue E: Detection and
partial characterization of dissolved glycoproteins in oceanic
waters. Limnol Oceanogr. 48:1037–1048. 2003. View Article : Google Scholar
|
|
33
|
Tomai E, Butz K, Lohrey C, von Weizsacker
F, Zentgraf H and Hoppe-Seyler F: Peptide aptamer-mediated
inhibition of target proteins by sequestration into aggresomes. J
Biol Chem. 281:21345–21352. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Butz K, Denk C, Fitscher B, et al: Peptide
aptamers targeting the hepatitis B virus core protein: a new class
of molecules with antiviral activity. Oncogene. 20:6579–6586. 2001.
View Article : Google Scholar : PubMed/NCBI
|
